Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma

Toxicology

Volumn 281, Issue 1-3, 2011, Pages 7-14

  Schmidt, Andreas ^a   Braeuning, Albert ^a   Ruck, Peter ^b   Seitz, Guido ^c   Armeanu Ebinger, Sorin ^c   Fuchs, Joerg ^c   Warmann, Steven W ^c   Schwarz, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Institute of Pathology   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Drug metabolism; Gene expression; Liver tumour; Wilms tumour; Wnt Catenin signalling

Indexed keywords

BETA CATENIN; CYTOCHROME P450; CYTOSTATIC AGENT; GLUTAMATE AMMONIA LIGASE; ISOENZYME;

ARTICLE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL INTERACTION; CELL PROLIFERATION; CHILDHOOD CANCER; CYTOSTASIS; EPITHELIUM TUMOR; HEPATOBLASTOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; MESENCHYMOMA; METABOLISM; MUTATION; NEPHROBLASTOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL;

BETA CATENIN; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE-AMMONIA LIGASE; HEPATOBLASTOMA; HUMANS; ISOENZYMES; LIVER NEOPLASMS; POINT MUTATION;

EID: 79851513349     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2011.01.006     Document Type: Article

References (35)

1. Armengol C., Cairo S., Fabre M., Buendia M.A. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int. J. Biochem. Cell Biol. 2009, doi:10.1016/j.biocel.2009.07.012.
2. Braeuning A., Sanna R., Huelsken J., Schwarz M. Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1. Drug Metab. Dispos. 2009, 37:1138-1145.
3. Cairo S., Armengol C., De Reynies A., Wei Y., Thomas E., Renard C.A., Goga A., Balakrishnan A., Semeraro M., Gresh L., Pontoglio M., Strick-Marchand H., Levillayer F., Nouet Y., Rickman D., Gauthier F., Branchereau S., Brugieres L., Laithier V., Bouvier R., Boman F., Basso G., Michiels J.F., Hofman P., Arbez-Gindre F., Jouan H., Rousselet-Chapeau M.C., Berrebi D., Marcellin L., Plenat F., Zachar D., Joubert M., Selves J., Pasquier D., Bioulac-Sage P., Grotzer M., Childs M., Fabre M., Buendia M.A. Hepatic stem-like phenotype and interplay of Wnt/β-Catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008, 14:471-484.
4. Chen L., Davis G.J., Crabb D.W., Lumeng L. Intrasplenic transplantation of isolated periportal and perivenous hepatocytes as a long-term system for study of liver-specific gene expression. Hepatology 1994, 19:989-998.
5. Douglass E.C., Reynolds M., Finegold M., Cantor A.B., Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 1993, 11:96-99.
6. Fuchs J., Rydzynski J., von Schweinitz D., Bode U., Hecker H., Weinel P., Burger D., Harms D., Erttmann R., Oldhafer K., Mildenberger H. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002, 95:172-182.
7. Gebhardt R., Mecke D. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal cells in situ and in primary culture. EMBO J. 1983, 2:567-570.
8. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 2003, 1653:1-24.
9. Kerbusch T., Jansen R.L., Mathot R.A., Huitema A.D., Jansen M., van Rijswijk R.E., Beijnen J.H. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin. Pharmacol. Ther. 2001, 70:132-141.
10. Kitada M., Tsukidate K., Takeuchi J., Taneda M., Komori M., Ohi H., Itahashi K., Kamataki T. Immunochemical studies for the presence of P-450 HFLa, a form of cytochrome P-450 in human fetal livers in human hepatocellular carcinoma cells. J. Pharmacobiodyn. 1989, 12:341-344.
11. Kobrinsky N.L., Sjolander D.E., Goldenberg J.A., Ortmeier T.C. Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue. Pediatr. Blood Cancer 2005, 45:222-225.
12. Koch A., Weber N., Waha A., Hartmann W., Denkhaus D., Behrens J., Birchmeier W., von Schweinitz D., Pietsch T. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J. Pathol. 2004, 204:546-554.
13. Komatsu T., Yamazaki H., Shimada N., Nagayama S., Kawaguchi Y., Nakajima M., Yokoi T. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Clin. Cancer Res. 2001, 7:675-681.
14. Kruithof-de Julio M., Labruyere W.T., Ruijter J.M., Vermeulen J.L., Stanulovic V., Stallen J.M., Baldysiak-Figiel A., Gebhardt R., Lamers W.H., Hakvoort T.B. The RL-ET-14 cell line mediates expression of glutamine synthetase through the upstream enhancer/promoter region. J. Hepatol. 2005, 43:126-131.
15. Kuo F.C., Darnell J.E. Evidence that interaction of hepatocytes with the collecting (hepatic) veins triggers position-specific transcription of the glutamine synthetase and ornithine aminotransferase genes in the mouse liver. Mol. Cell. Biol. 1991, 11:6050-6058.
16. Kusafuka T., Miao J., Kuroda S., Udatsu Y., Yoneda A. Codon 45 of the β-Catenin gene, a specific mutational target site of Wilms' tumor. Int. J. Mol. Med. 2002, 10:395-399.
17. Lemieux G., Baverel G., Vinay P., Wadoux P. Glutamine synthetase and glutamyltransferase in the kidney of man, dog, and rat. Am. J. Physiol. 1976, 231:1068-1073.
18. Loeppen S., Schneider D., Gaunitz F., Gebhardt R., Kurek R., Buchmann A., Schwarz M. Overexpression of glutamine synthetase is associated with β-Catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 2002, 62:5685-5688.
19. Loeppen S., Koehle C., Buchmann A., Schwarz M. A β-Catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 2005, 26:239-248.
20. Lopez-Terrada D., Gunaratne P.H., Adesina A.M., Pulliam J., Hoang D.M., Nguyen Y., Mistretta T.A., Margolin J., Finegold M.J. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and notch pathway activation in DLK+ precursors. Hum. Pathol. 2009, 40:783-794.
21. Lu H., Waxman D.J. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. Mol. Pharmacol. 2005, 67:212-219.
22. Lu Y., Cederbaum A.I. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci. 2006, 89:515-523.
23. Miao J., Kusafuka T., Udatsu Y., Okada A. Sequence variants of the axin gene in hepatoblastoma. Hepatol. Res. 2003, 25:174-179.
24. Oda H., Imai Y., Nakatsuru Y., Hata J., Ishikawa T. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res. 1996, 56:3320-3323.
25. Perilongo G., Maibach R., Shafford E., Brugieres L., Brock P., Morland B., de Camargo B., Zsiros J., Roebuck D., Zimmermann A., Aronson D., Childs M., Widing E., Laithier V., Plaschkes J., Pritchard J., Scopinaro M., MacKinlay G., Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N. Engl. J. Med. 2009, 361:1662-1670.
26. Sinclair J., Jeffery E., Wrighton S., Kostrubsky V., Szakacs J., Wood S., Sinclair P. Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem. Pharmacol. 1998, 55:1557-1565.
27. Stahl S., Ittrich C., Marx-Stoelting P., Kohle C., Altug-Teber O., Riess O., Bonin M., Jobst J., Kaiser S., Buchmann A., Schwarz M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 2005, 42:353-361.
28. Stiller C.A., Pritchard J., Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 2006, 42:2115-2123.
29. Stocker J.T., Schmid D. Pathology and genetics of tumours of the digestive system, hepatoblastoma. World Health Organization Classification of Tumors 2000, International Agency for Research on Cancer (IARC) Press, Lyon, France, pp. 184-189.
30. Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M., Nagorney D.M., Burgart L.J., Roche P.C., Smith D.I., Ross J.A., Liu W. Mutational spectrum of β-Catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21:4863-4871.
31. Udatsu Y., Kusafuka T., Kuroda S., Miao J., Okada A. High frequency of β-Catenin mutations in hepatoblastoma. Pediatr. Surg. Int. 2001, 17:508-512.
32. von Schweinitz D., Byrd D.J., Hecker H., Weinel P., Bode U., Burger D., Erttmann R., Harms D., Mildenberger H. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma, Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur. J. Cancer 1997, 33:1243-1249.
33. Vujanic G.M., Sandstedt B., Harms D., Kelsey A., Leuschner I., de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med. Pediatr. Oncol. 2002, 38:79-82.
34. Wei Y., Fabre M., Branchereau S., Gauthier F., Perilongo G., Buendia M.A. Activation of β-Catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000, 19:498-504.
35. Willert K., Nusse R. β-Catenin: a key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 1998, 8:95-102.